
zzso of zzso by zzso zzso durable responses in many patients with chronic zzso leukemia zzso but resistance attributable to zzso domain zzso can lead to zzso and a switch to zzso therapy with zzso or zzso Despite three approved therapeutic options, the zzso zzso zzso and compound zzso selected on sequential inhibitor therapy remain major clinical zzso We report design and zzso evaluation of zzso a zzso orally available zzso zzso inhibitor active against zzso and other zzso zzso zzso inhibited all tested zzso zzso in cellular and zzso zzso suppressed zzso tumor growth in mice, and completely zzso resistance in zzso zzso zzso Our work supports clinical evaluation of zzso as a zzso inhibitor for treatment of zzso 

